ARQT · XBRL financial data

Arcutis Biotherapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARQT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	4	60	197	376
Cost of goods and services sold	—	0	1	5	19	37
Research and development	115	146	182	111	76	77
Selling, general and administrative	—	61	122	185	229	275
General and administrative	21	61	122	—	—	—
Total operating expenses	137	207	305	—	—	—
Operating income (loss)	(137)	(207)	(302)	(241)	(128)	(12)
Interest expense	0	0	16	30	27	12
Other income (expense)	1	0	6	12	16	0
Income tax expense (benefit)	0	0	0	3	1	1
Net income (loss)	(136)	(206)	(311)	(262)	(140)	(16)
Earnings per share, basic USD per share	(3.80)	(4.18)	(5.66)	(3.78)	(1.16)	(0.13)
Earnings per share, diluted USD per share	(3.80)	(4.18)	(5.66)	(3.78)	(1.16)	(0.13)
Weighted average shares, basic millions of shares	36	49	55	69	121	127
Weighted average shares, diluted millions of shares	36	49	55	69	121	127

Fiscal years (ARQT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	65	96	54	88	71	43
Marketable securities	219	291	356	183	157	178
Accounts receivable	—	0	8	26	73	146
Inventory	—	0	8	13	15	23
Prepaid and other current assets	7	14	11	19	20	21
Total current assets	293	403	437	330	336	411
Property and equipment, net	2	2	2	2	1	1
Right-of-use asset	3	3	3	2	2	4
Total assets	298	408	449	341	349	433
Accounts payable	7	7	9	12	14	13
Accrued liabilities	15	26	28	34	66	116
Current portion of long-term debt	—	—	—	0	0	1
Total current liabilities	23	33	38	47	81	130
Long-term debt	0	72	198	202	107	108
Lease liability, non-current	5	5	4	3	3	5
Total liabilities	28	110	240	253	191	243
Accumulated deficit	(202)	(408)	(720)	(982)	(1,122)	(1,138)
Total stockholders' equity	271	298	210	89	158	189
Total liabilities and equity	298	408	449	341	349	433
Common shares outstanding (cover page) millions of shares	50	50	61	97	119	124

Fiscal years (ARQT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(136)	(206)	(311)	(262)	(140)	(16)
Stock-based compensation	8	24	33	39	42	40
Net cash from operating activities	(113)	(175)	(258)	(247)	(112)	(6)
Purchases of property and equipment	0	1	0	0	0	1
Net cash from investing activities	(182)	(76)	(87)	180	29	(30)
Proceeds from issuing common stock	128	207	162	0	162	0
Proceeds from long-term debt	0	74	125	0	0	—
Repayments of long-term debt	—	—	0	0	100	0
Net cash from financing activities	298	282	302	101	66	7
Net change in cash	3	31	(43)	34	(17)	(29)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arcutis Biotherapeutics	33	144	19*	126.5M	—	Q3 FY26 10-QSep 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	76	84	9.6*	161.9M	—	Q3 FY26 10-QSep 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.